P-118 - A PHASE I STUDY TO EVALUATE ABSOLUTE BIOAVAILABILITY AND ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION (ADME) OF SAVOLITINIB IN HEALTHY MALE VOLUNTEERS.

K. Miah¹, K. Vishwanathan¹, G. Scarfe², Y. Li³, I. Hara², M. Cantarini², J. Argue², S. Menakuru⁴; ¹AstraZeneca, Waltham, MA, USA, ²AstraZeneca, Cambridge, United Kingdom, ³AstraZeneca, Boston, MA, USA, ⁴Quotient Sciences, Nottingham, United Kingdom.